Quantum Biopharma Ltd. (QNTM) — 20-F Filings
All 20-F filings from Quantum Biopharma Ltd.. Browse 3 Foreign Annual Report reports with AI-powered summaries and risk analysis.
20-F Filings (3)
-
Quantum Biopharma Eyes Phase 2 for MS Drug, Consolidates Shares
— Mar 26, 2026 Risk: high
Quantum Biopharma Ltd. (QNTM) filed its 20-F for the fiscal year ended December 31, 2025, reporting its financial statements under IFRS. The company's primary f -
Quantum Biopharma Files 20-F, Reports Assets & Liabilities
— Mar 28, 2025 Risk: medium
Quantum Biopharma Ltd. (formerly FSD Pharma Inc.) filed its 20-F for the fiscal year ending December 31, 2024. The company, incorporated in A6 and headquartered -
FSD Pharma Inc. Files 20-F Report for Fiscal Year Ended December 31, 2023
— Apr 2, 2024 Risk: high
FSD Pharma Inc. (QNTM) filed a Foreign Annual Report (20-F) with the SEC on April 2, 2024. FSD Pharma Inc. completed a Plan of Arrangement reorganization, cance
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX